公开(公告)号：US20200078439A1

公开(公告)日：2020-03-12

申请号：US16510442

申请日：2019-07-12

Applicant: Immatics Biotechnologies GmbH

Inventor： Hans Georg RAMMENSEE ,  Stefan STEVANOVIC ,  Cecile GOUTTEFANGEAS ,  Toni WEINSCHENK ,  Peter LEWANDROWSKI

IPC: A61K38/10 ,  C07K16/18 ,  C07K7/08 ,  A61K39/00 ,  C07K14/705 ,  C07K14/47

Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.